Max W Sung, MD
img_Max W Sung
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Internal Medicine, Cancer (Oncology), Hematology-Oncology

Dr. Sung is currently conducting clinical trials of immunotherapy in patients with advanced colorectal and breast cancers using gene transfer therapy. He is also involved in clinical trials of suicide gene therapy and differentiation therapies for colorectal cancer, and anti-angiogenesis therapy for hepatocellular carcinoma.

Dr. Sung actively participates in multi-modality treatment approaches (surgery/radiation/chemotherapy) to cancers of the liver, colon-rectum, carcinoid, pancreas, esophagus, stomach and anal cancers, and is also experienced in regional treatment modalities such as hepatic arterial chemotherapy/chemoembolization and intraperitoneal chemotherapy.

MD, Yeshiva University Albert Einstein College of Medicine

Internship, Internal Medicine, Montefiore Medical Center

Residency, Internal Medicine, Montefiore Medical Center

Fellowship, Hematology, Montefiore Medical Center


American Board of Internal Medicine

Selected Publications

Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma. Kirema Garcia-Reyes, Ricki A. Gottlieb, Kartikeya M. Menon, Vivian Bishay, Rahul Patel, Rajesh Patel, Scott Nowakowski, Max W. Sung, Thomas U. Marron, William H. Gansa, Jack Zhang, Sahitya C. Raja, Daniel Shilo, Aaron Fischman, Robert Lookstein, Edward Kim. Journal of Vascular and Interventional Radiology

Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study. Fabio Piscaglia, Kenji Ikeda, Ann Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, Valery Breder, Baek Yeol Ryoo, Kalgi Mody, Min Ren, Zahra Ramji, Max W. Sung. Cancer

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, Valeriy Breder, Hiromitsu Kumada, Ann Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer Knox, Janine Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis Villanueva, Patricio Yanez Weber, Marcelo Garrido, Gonzalo Ignacio Pizarro, Nicolas Yanez, Shuangyan Ou, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Max Sung. The Lancet Oncology

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sung during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • AstraZeneca AB

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.